Replimune to Present at the William Blair Biotech Focus Conference 2021
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) --Replimune, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.
A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.
Westwicke, an ICR Company
Verge Scientific Communications
202.930.4762 x 409